Related Experiment Videos
Ca2+ mobilization during cell death induction by sodium 5, 6-benzylidene-L-ascorbate
H Takahashi1, H Sakagami, H Ohata
1First Department of Biochemistry, School of Medicine, Showa University, Tokyo, Japan.
Anticancer Research
|September 1, 1996
Summary
Sodium 5,6-benzylidene-L-ascorbate (SBA) enhances cancer cell death, particularly when combined with L-buthionine-[S, R]-sulfoximine (BSO). This combination increases intracellular calcium, suggesting nuclear calcium accumulation is key to inducing cell death in glioma and glioblastoma.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Glutathione depletion can sensitize cancer cells to cytotoxic agents.
- Calcium signaling plays a critical role in cellular processes, including apoptosis.
- Sodium 5,6-benzylidene-L-ascorbate (SBA) exhibits cytotoxic effects on cancer cells.
Purpose of the Study:
- To investigate the effect of L-buthionine-[S, R]-sulfoximine (BSO) on the cytotoxic activity of SBA against human glioma and glioblastoma cell lines.
- To elucidate the role of intracellular calcium and glutathione in SBA-induced cell death.
Main Methods:
- Cell culture of human KG-1-C glioma and T98G glioblastoma cell lines.
- Treatment with SBA and BSO, a glutathione-depleting agent.
- Assessment of cytotoxicity, DNA fragmentation, and intracellular free Ca2+ concentrations using techniques like confocal microscopy with Fluo-3 fluorescence.
Main Results:
- BSO pretreatment augmented the cytotoxic activity of SBA against both cell lines.
- SBA treatment induced cell shrinkage and large DNA fragments, but not internucleosomal fragmentation.
- SBA rapidly elevated intracellular free Ca2+ concentrations, an effect further enhanced by BSO.
- Confocal microscopy revealed SBA-induced Ca2+ elevation primarily in the nuclear region.
Conclusions:
- Nuclear calcium accumulation is a critical initial step in SBA-induced cell death.
- BSO enhances SBA cytotoxicity by further increasing intracellular calcium levels.
- The findings suggest a potential therapeutic strategy combining SBA with glutathione-depleting agents for glioma and glioblastoma treatment.